Introducing ACI’s Biosimilars & Innovator Biologics Advisory Board

American Conference Institute’s Biosimilars & Innovator Biologics Advisory Board was created as a part of ACI’s ongoing effort to provide industry leading content and a world-renowned speaker faculty. The board is composed of a selection of all-in-house advisers, including senior IP/Patent counsel from the leading pharmaceutical companies in the country and in some cases the world. This ‘inner circle’ counsels ACI on the impact of litigation trends and emerging topics.

Ali I. Ahmed

Senior Vice President, Biosimilars
Fresenius Kabi USA

Neal Dahiya

SVP, Head of Litigation

Henry Gu

Vice President, Head of IP
Morphic Therapeutic

Brian McCormick

Vice President - Chief Regulatory Counsel, Head of Global Regulatory Policy
Teva Pharmaceuticals

Sonia Oskouei

Vice President, Biosimilars
Cardinal Health

Julia Pike

Global Head of IP

Charles K. Sholtz, PhD, JD

Director and AGC, Manufacturing IP Lead
Intellectual Property
Genentech | A Member of the Roche Group

Gillian Woollett

VP, Head Regulatory Strategy and Policy
Samsung Bioepis